Annual report pursuant to Section 13 and 15(d)

Consolidated Balance Sheets

v3.21.2
Consolidated Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2021
Jun. 30, 2020
Current assets    
Cash and cash equivalents $ 10,537 $ 2,392
Prepaid expenses, deposits and other 756 365
Clinical trial deposit 500  
Deferred loan costs   94
Total current assets 11,793 2,851
Clinical trial deposit 1,600  
Property, equipment and intangibles - net 150 2
Deferred financing costs   85
Total assets 13,543 2,938
Current liabilities    
Accounts payable and accrued liabilities 2,219 2,011
Related party payables 561 664
Total current liabilities 2,780 2,675
Milestone payment liability 182  
Total liabilities 2,962 2,675
Stockholders’ equity    
Common stock Authorized 175,000 shares at June 30, 2021 (June 30, 2020 - 95,000) $0.001 par value 32,740 issued at June 30, 2021 (June 30, 2020 – 11,458) 33 11
Additional paid-in capital 106,821 65,148
Accumulated deficit (111,225) (69,721)
Accumulated other comprehensive income 21 21
Total stockholders’ equity 10,581 263
Total liabilities and stockholders’ equity 13,543 2,938
Preferred Stock Series A    
Stockholders’ equity    
Preferred stock 279 279
Preferred Stock Series B    
Stockholders’ equity    
Preferred stock   4,525
Total stockholders’ equity   $ 4,525
Preferred Stock Series C    
Stockholders’ equity    
Preferred stock $ 14,652